| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| Antero Midstream Partners LP (AM) | Barclays/ Citigroup/ Wells Fargo Securities | $500.00 | n.a. | |||
| Bio Blast Pharma Ltd. (TBA) | Aegis Capital Corp | $37.50 | n.a. | |||
| Diamond S Shipping Group (DSG) | Jefferies/ BofA Merrill Lynch | $100.00 | n.a. | |||
| Dipexium Pharmaceuticals (DPRX) | Oppenheimer & Co. | $34.50 | n.a. | |||
| Galmed Pharmaceuticals Ltd. (GLMD) | Maxim Group LLC | $34.50 | n.a. | |||
| Rubicon Project (The) (RUBI) | Morgan Stanley/ Goldman Sachs/ RBC Capital Markets, LLC | $100.00 | n.a. | |||
| n.a. (not available) | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| Grassmere Acquisition (TBA) | Lazard Capital Markets | 5.00 | $10.00 | $10.00 | $50.00 | 1-Star |
| New Terms | ||||||
| Auspex Pharmaceuticals (ASPX) | Stifel/ BMO Capital Markets | 5.50 | $10.00 | $12.00 | $60.50 | 2-Stars |
| Boulevard Acquisition (BLVDU) | Citigroup | 15.00 | $10.00 | $10.00 | $150.00 | 1-Star |
| Concert Pharmaceuticals (CNCE) | UBS Investment Bank/ Wells Fargo Securities | 5.00 | $12.00 | $14.00 | $65.00 | 2-Stars |
| Inogen (INGN) | J.P. Morgan/ Leerink Swann | 4.41 | $16.00 | $18.00 | $75.00 | 2-Stars |
| Installed Building Products (IBP) | Deutsche Bank Securities/ UBS Investment Bank | 9.00 | $14.00 | $16.00 | $135.00 | 1-Star |
| Sundance Energy Australia Limited (SEA) | Wells Fargo Securities/ Canaccord Genuity/ UBS Investment Bank | 7.75 | $16.50 | $18.50 | $135.63 | N/C |
| N/C – The ordinary shares are listed on the Australian Securities Exchange | ||||||
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of Feb. 3, 2014 | Manager(s) | Offered | Raised | Price | 2/7/14 | Change |
| Revance Therapeutics (RVNC) | Cowen and Company/ Piper Jaffray | 6.00 | $96.00 | $16.00 | $28.00 | 75.00% |
| Auspex Pharmaceuticals (ASPX) | Stifel/ BMO Capital Markets | 7.00 | $84.00 | $12.00 | $17.65 | 47.08% |
| Continental Building Products (CBPX) | Citigroup/ Credit Suisse/ Barclays/ Deutsche Bank Securities/ RBC Capital Markets | 11.77 | $164.71 | $14.00 | $17.30 | 23.57% |
| Eleven Biotherapeutics (EBIO) | Citigroup/ Cowen and Company/ Leerink Swann | 5.00 | $50.00 | $10.00 | $11.15 | 11.50% |
| CM Finance (CMFN) | Raymond James/ Keefe, Bruyette & Woods (A Stifel Company)/ Oppenheimer | 6.67 | $100.00 | $15.00 | $15.95 | 6.33% |
| Ladder Capital (LADR) | Deutsche Bank Securities/ Citigroup/ Wells Fargo Securities/ BofA Merrill Lynch/ J.P. Morgan | 13.25 | $225.25 | $17.00 | $17.30 | 1.76% |
| Egalet (EGLT) | Stifel/ JMP Securities | 4.20 | $50.40 | $12.00 | $12.00 | 0.00% |
| Argos Therapeutics (ARGS) | Piper Jaffray/ Stifel/ JMP Securities | 5.63 | $45.00 | $8.00 | $8.00 | 0.00% |
| GeoPark Ltd (GPRK) | J.P. Morgan/ BTG Pactual/ Itaú BBA | 13.50 | $94.50 | $7.00 | $6.45 | -7.86% |
| Genocea Biosciences (GNCA) | Citigroup/ Cowen and Company | 5.50 | $66.00 | $12.00 | $11.04 | -8.00% |
| Biocept (BIOC ) | Aegis Capital | 1.90 | $19.00 | $10.00 | $8.90 | -11.00% |
| uniQure B.V. (QURE) | Jefferies/ Leerink Swann | 5.40 | $91.80 | $17.00 | $14.79 | -13.00% |
